Use of camptothecin derivatives, with reduced gastrointestinal toxicity

A medicinal product comprising:

• a) a first solution comprising one or more camptothecin derivatives, wherein the derivative is of the formula:
• and wherein
• R1 is a hydrogen, halogen, or alkyl,
• X is a chloride atom or NR2R3, wherein R2 and R3, which may be identical or different, can represent a hydrogen atom, an optionally substituted alkyl radical, a carbocycle or a heterocycle which are optionally substituted, or alkyl radicals (optionally substituted) forming, with the nitrogen atom to which they are attached, a heterocycle optionally containing another hetero atom chosen from O, S, and/or NR4, R4 being a hydrogen atom or an alkyl radical, and in which the X—CO—O— group is located in positions 9, 10, or 11 on ring A, and
• b) sodium chloride which is administered orally during, or before and during, the administration of the first solution,
• further comprising one or more anticancer agents selected from the group consisting of cisplatin, oxaliplatin, N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-theonyl-L-glutamic acid)), docetaxel, 5-fluorouracyl and thymidilate synthase inhibitors.

A method of treating a cancer by administering to a patient an effective amount of a medicinal product comprising:

• a) a first solution comprising one or more camptothecin derivatives, wherein the derivative is of the formula:
• and wherein
• R1 is a hydrogen, halogen, or alkyl,
• X is a chloride atom or NR2R3, wherein R2 and R3, which may be identical or different, can represent a hydrogen atom, an optionally substituted alkyl radical, a carbocycle or a heterocycle which are optionally substituted, or alkyl radicals (optionally substituted) forming, with the nitrogen atom to which they are attached, a heterocycle optionally containing another hetero atom chosen from O, S, and/or NR4, R4 being a hydrogen atom or an alkyl radical, and in which the X—CO—O— group is located in positions 9, 10, or 11 on ring A;
• b) a second solution consisting essentially of a sodium chloride solution, wherein the second solution is administered orally during, or before and during, the administration of the first solution, and
• c) wherein the second solution eliminates or reduces the gastrointestinal side effects associated with the administration of camptothecin derivatives alone.